Welcome to our dedicated page for Regenerx Biopharmaceuticals news (Ticker: RGRX), a resource for investors and traders seeking the latest updates and insights on Regenerx Biopharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regenerx Biopharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regenerx Biopharmaceuticals's position in the market.
On Sept. 8, 2020, RegeneRx Biopharmaceuticals (OTCQB: RGRX) announced that a research paper highlights the potential of Thymosin beta 4 (Tβ4) in treating COVID-19. The study indicates Tβ4 may induce fibrinolysis, reducing blood clots in patients. Researchers noted that men suffering from COVID-19 are significantly more at risk compared to women, possibly due to genetic factors linked to Tβ4. The findings suggest Tβ4 could mitigate serious symptoms of COVID-19, especially in vulnerable populations. RegeneRx continues to develop Tβ4-based therapies, including a candidate for COVID-19 treatment.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) announced that its joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome. The trial, which experienced delays due to COVID-19, now includes 19 clinical sites and is set to enroll 700 patients by November 2020. RGN-259 eye drops have shown promising efficacy in previous trials and are now classified as biologics, offering 12 years of market exclusivity upon FDA approval. The joint venture also plans a Phase 3 study for neurotrophic keratopathy.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) announced an update on its Phase 3 dry eye clinical trial (ARISE-3) enrollment status. The company is developing Tβ4 therapeutic peptides for tissue protection and regeneration. Currently, RegeneRx has three drug candidates under clinical development for various medical indications, including ophthalmic and cardiac uses. The ophthalmic product RGN-259 is particularly noted for its Phase 3 trials aimed at treating dry eye syndrome and neurotrophic keratitis in the U.S.